Ipamorelin vs GHRP-2
Head-to-head comparison of Ipamorelin and GHRP-2 for research applications. Both peptides are studied for Body Composition, but they differ significantly in mechanism, evidence level, and dosing protocols.
Side-by-Side Comparison
| Attribute | Ipamorelin | Ghrp 2 |
|---|---|---|
| Category | Growth Hormone Secretagogue | Growth Hormone Secretagogue |
| Mechanism | Ipamorelin (sequence: Aib-His-D-2Nal-D-Phe-Lys-NH2) selectively binds to the Growth Hormone Secretagogue Receptor (GHS-R1a) on anterior pituitary somatotroph cells, increasing cAMP and activating protein kinase A to promote pulsatile GH secretion. | GHRP-2 (C45H55N9O6) binds to and activates ghrelin (GH secretagogue) receptors on pituitary somatotrophs, triggering robust pulsatile GH release. |
| Evidence Rating | D — Preclinical | C — Phase I–II Clinical Trials |
| Clinical Status | Research-only / Not approved for human use | Approved in Japan for GH deficiency diagnosis; research-only elsewhere |
| Safety Profile | Widely regarded as the mildest GHS available; minimal side effects in published animal and human studies; Common: injection site reactions (redness, swelling, bruising) in 15-30% of users, resolving within 24-48 hours | Well tolerated in clinical trials with placebo-like safety profile at therapeutic ranges; May increase appetite (less than GHRP-6) |
| Route | Subcutaneous | Subcutaneous |
| Dose Range | 100–300 mcg per injection, 2–3x daily | 100–300 mcg per injection, 2–3x daily |
| Frequency | 2–3 times daily (typically before meals and before bed) | 2–3 times daily |
| Molecular Weight | ~711.9 g/mol | ~817.0 g/mol |
| Half-Life | ~2 hours | ~15–60 minutes |
Overview
Ipamorelin and GHRP-2 are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
Ipamorelin — Mechanism & Evidence
Ipamorelin is the most selective growth hormone secretagogue (GHS) available, a synthetic pentapeptide (MW ~711.86 g/mol, formula C38H49N9O5) that stimulates pulsatile GH release from the pituitary gland without significantly affecting cortisol, prolactin, or appetite. It is widely regarded as the mildest GHS, making it popular in anti-aging, body composition, and recovery contexts. However, research on ipamorelin is limited, and it is not FDA-approved for any indication.
Key claims: Increases growth hormone levels; Improves body composition; Improves sleep quality.
BPC-157 5mg
5mg
GHRP-2 — Mechanism & Evidence
GHRP-2 (pralmorelin) is a synthetic hexapeptide growth hormone secretagogue (D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2, MW ~817.97 g/mol) that stimulates potent, dose-dependent GH release via the ghrelin receptor (GHS-R). It is considered more potent than GHRP-6 with less appetite stimulation. Approved in Japan as a diagnostic agent for GH deficiency (pralmorelin), it has been used clinically in GH-deficient children for 8-24 months with maintained efficacy on growth velocity. Clinical studies show a placebo-like safety profile at therapeutic doses.
Key claims: Potent growth hormone release; Diagnostic tool for GH deficiency; Sustained efficacy in long-term use.
Shared Research Applications
Both peptides are studied for: Body Composition.
Ipamorelin is also researched for: Anti-Aging, Sleep.
GHRP-2 is also researched for: no additional unique applications.
Safety Considerations
Ipamorelin: Widely regarded as the mildest GHS available; minimal side effects in published animal and human studies Common: injection site reactions (redness, swelling, bruising) in 15-30% of users, resolving within 24-48 hours Common: mild temporary "head rush" or flushing immediately after injection due to sudden vasodilation
GHRP-2: Well tolerated in clinical trials with placebo-like safety profile at therapeutic ranges May increase appetite (less than GHRP-6) Can elevate cortisol and prolactin levels (less than GHRP-6)
Shop Research Peptides
BPC-157 5mg
5mg
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
GHK-Cu 50mg
50mg
Tesamorelin 10mg
10mg
BPC-157 10mg
10mg
Tirzepatide 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
Ipamorelin vs GHRP-2: Which Offers More Targeted GH Release?
Ipamorelin and GHRP-2 both stimulate growth hormone release via the ghrelin receptor, but Ipamorelin provides more selective action with minimal impact on other hormones like ACTH and cortisol. GHRP-2 delivers stronger GH pulses alongside broader endocrine effects. Combining them can enhance overall GH output through additive receptor stimulation.
Tesamorelin vs Ipamorelin: Evidence, Uses, Risks
This article compares tesamorelin and ipamorelin based on published human evidence, highlighting what is known about their uses and risks and where direct comparative data is missing.
CJC-1295 and Ipamorelin: Human Evidence and Limits
This reference separates what human trials, animal models, and analytical chemistry show about CJC-1295 and ipamorelin from vendor marketing, assessing the strength of the human evidence base and combination-specific safety data.
Peptide Tools
Follow Research Updates
Get new research pages, product updates, tool releases, and quality resources from Volta.
Subscribe